TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (OADs) for at least 6 months before screening visit;~Exclusion criteria:~* Age \< 18 years at screening visit;~* BMI(body mass index) ≥ 35 kg/m2 at screening visit;~* HbA1c \< 7.0% or \> 10% (national glycohemoglobin standardization program \[NGSP\] value) at screening visit;~* Diabetes other than type 2 diabetes mellitus;~* Patients on self-monitoring of blood glucose less than 6 months before screening visit;~* Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1 receptor agonists in the last 3 months before screening visit;~* Patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit;~* Use of insulin pump in the last 6 months before screening visit;~* Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit;~* Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit;~* Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New formulation of insulin glargine (Type: EXPERIMENTAL): once daily in the evening on-top of oral antihyperglycemic drug (OADs)
- Lantus (insulin glargine) (Type: ACTIVE_COMPARATOR): once daily in the evening on-top of OADs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male aged 18-55 years (both inclusive) at the time of signing informed consent~* Body mass index (BMI) between 18.5-28.0 kg/m\^2 (both inclusive)~* Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs and clinical laboratory tests performed during the screening visit, as judged by the investigator~* Normal electrocardiogram (ECG) at screening or minor findings considered not clinically significant, as judged by the investigator~Exclusion Criteria:~* Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per week), or subject smoking equal to or less than 5 cigarettes or the equivalent per week who is not able or willing to refrain from smoking and use of nicotine substitute products within 48 hours prior to each dosing and during the in-patient periods~* Any blood draw in excess of 25 mL in the past month, or donation of blood or plasma in excess of 400 mL within the 3 months preceding screening~* Sitting blood pressure at screening (after resting for at least 5 minutes) outside the range of 90-139 mmHg for systolic or 50-89 mmHg for diastolic~* History of major surgical procedures involving the stomach potentially affecting absorption of trial product (e.g. subtotal and total gastrectomy, sleeve gastrectomy,gastric bypass surgery)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Part A, SNAC (Type: EXPERIMENTAL): Single dose of 1.2mg, 2.4mg or 3.6mg increasing for each cohort of trial participants.
- Part A, placebo (Type: PLACEBO_COMPARATOR): Single dose at corresponding dose levels.
- Part B, SNAC, Placebo, Moxifloxacin (Type: EXPERIMENTAL): Subjects will receive 4 different treatments in random order. SNAC dose between 1.2-3.6 mg, Placebo in two different periods, moxifloxacin 400mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Non-falciparum Malaria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the age of 6 months and 60 years and with a minimum of 5kg bodyweight~* Presence of uncomplicated malaria confirmed by: i)fever or history of fever in the previous 4 days, and ii)positive microscopy of P. malariae or P. ovale or mixed infection with P.falciparum with parasite density \> 50-200000/μl of blood~* Written informed consent~Exclusion Criteria:~* Patients with presence of other clinical conditions requiring hospitalization~* Presence of other febrile conditions~* Presence of significant anemia, defined by hemoglobin \< 7g/dl~* Known history of hypersensitivity,allergic or adverse reactions to artemether or lumefantrine~* Intake of any antimalarial or antibiotics with known antimalarial activity in the preceding 2 weeks~* Pregnant and breast feeding females

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years~* suspected primary brain tumor by imaging~* planned bioptical or cytoreductive surgery of the tumor~* symptomatic epilepsy~* Karnofsky performance score ≥ 70%~* women with child bearing potential must perform sufficient contraception~* sufficient haematologic, hepatic and renal function by laboratory testing~Exclusion Criteria:~* treatment with other antiepileptic drugs other than levetiracetam in the last seven days before surgery~* known allergic reaction to levetiracetam or other serious side effects~* known, not tumor-induced, epilepsy~* previous brain surgery~* dementia~* participation in another clinical trial~* addiction to drugs or alcohol~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have Stage 3B or 4 Non-Small Cell Lung Cancer of the non- squamous type~* Patients must at least be able to be physically mobile, take care of yourself and be able to perform light activities such as light housework or office work~* Patients must not have had previous chemotherapy treatment for lung cancer~* Patients must not have had radiotherapy in the last 30 days~* Patients must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines or disease that can be evaluated on computed tomography (CT) scan~* Patients' test results assessing the function of their blood forming tissue, kidneys, liver and lungs are satisfactory~* Women must be sterile, postmenopausal or on contraception and men must be sterile or on contraception~Exclusion Criteria:~* Patients cannot have received other investigational drugs within the last 30 days~* Patients cannot have any serious, uncontrolled medical condition that might compromise their ability to take part in the study safely~* Patients cannot have a current second primary malignant tumor~* Patients cannot be having current treatment with any other anti-tumor therapy~* Patients cannot have had a yellow fever vaccination within 30 days of enrolment~* Patients who are unable to take vitamins (including injections of vitamin B12) or oral cortisone medication~* Patients who are unable to stop taking more than 1.3 grams of aspirin on a daily basis or non-steroidal anti-inflammatory agents~* Patients who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-squamous cell Non Small Cell Lung Cancer (NSCLC) disease~* Clinical stage IIIB/IV or recurrent disease after surgery~* No prior systemic chemotherapy, immunotherapy, targeted therapy or biological therapy, including adjuvant therapy~* Prior radiation therapy is allowed to less than 25% of the bone marrow~* Measurable disease as defined by response evaluation criteria in solid tumors (RECIST)~* The Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Adequate organ function~* Estimated life expectancy of at least 12 weeks~Exclusion Criteria:~* Clinically significant third-space fluid collections~* Central nervous system disease other than stable and treated brain metastasis~* More than 3 weeks interval between the surgery and enrollment request date~* Unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), for a 5 days period~* Unable or unwilling to take folic acid or vitamin B12 supplementation~* Unable to take corticosteroids.~* Serious concomitant disorder that, in the opinion of the investigator, would compromise the patient's ability to adhere to the protocol~* Currently have and historically had interstitial pneumonitis (interstitial pneumonia) or pulmonary fibrosis manifested as opacity on Chest x-ray or Computed tomography (CT)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Carboplatin (Type: EXPERIMENTAL): After four 21-day cycles of Pemetrexed plus Carboplatin treatment, Pemetrexed monotherapy is continued until study discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Motivational Interviewing and Neuroimaging With Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* within the specified age range~* \>= 1 past two month binge drinking episode~* right-handed~* proficient in English~* agree to be contacted for the 3, 6, and 12 month follow ups~* informed consent of a parent/guardian, if under 18 years old~* informed assent/consent of participating youth~Exclusion Criteria:~* \> 3 past-month instances of non-nicotine and/or non-cannabis substance use (e.g., methamphetamine)~* evidence of brain injury/illness or neurological disorder including psychosis~* lifetime loss of consciousness \>= 2 min~* unremovable metal on/in body, or other functional magnetic resonance imaging (fMRI) contraindications (e.g., pregnancy)

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Motivational Interviewing (MI) (Type: EXPERIMENTAL): This randomly assigned group receives two 60-minute 1:1 sessions of motivational interviewing.
- Brief Adolescent Mindfulness (BAM) (Type: ACTIVE_COMPARATOR): This randomly assigned group receives two 60-minute 1:1 sessions of Brief Adolescent Mindfulness.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated Bacteremia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients who have an indwelling hemodialysis catheter for 10 or more days and evidence of a catheter associated bloodstream infection as evidenced by 1)quantitative blood cultures obtained through the lumen of the catheter yield concentrations of bacterial colonies that are 5 or more fold higher than peripheral blood cultures, or 2)blood cultures obtained through the lumen of the catheter becomes positive 2 or more hours earlier than peripheral blood cultures.~Exclusion Criteria:~* Patients will be excluded if 1) they are unable or unwilling to provide informed consent, 2) have evidence of a complicated bacteremia such as endocarditis, septic thrombophlebitis, septic emboli, osetoemylitis, deep seated abscesses etc 3)evidence of an exit site infection around the catheter such as a pus pocket, drainage or erythema. 4) patient is allergic to NAC or the proposed antibiotic (if patient is allergic to minocycline, tigecycline will not be used). 5) patient is pregnant or will become pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): single arm trial of experimental catheter lock solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* history of rhinitis with hay fever symptoms during the grass pollen season,~* a skin-prick-test-verified grass pollen allergy (Phleum pratense),~* eligibility for immunotherapy based on ARIA guidelines~Exclusion Criteria:~* current long-term systemic steroid treatment,~* previous immunotherapy,~* asthma and outside-season airway hyperresponsiveness (AHR) (September 2011),~* pregnancy,~* negative RAST for grass, and~* treatment side effect

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: NO_INTERVENTION): None
- Subcutaneous Immunotherapy (SCIT) (Type: ACTIVE_COMPARATOR): Treatment using ALK AluTard 225 Phleum pratense
- Sublingual Allergen Immunotherapy Tablets (AIT) (Type: ACTIVE_COMPARATOR): Treatment using ALK Grazax 75,000 SQ-T Phleum pratense

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Determine if Chromium Nicotinate Supplementation Will Improve Insulin Resistance in HIV Patients With Metabolic Abnormalities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV documented patients will be considered for the study if they have at least one abnormality with respect to fasting blood glucose, TG, total or HDL cholesterol. Normal fasting glucose is defined as \< 6.1 mmol/L. Hypertriglyceridemia is defined as concentrations above 2.0 mmol/L on the basis of reports of increased risk of cardiac disease. Hypercholesterolemia is defined as concentrations above 5.5 mmol/L and a low HDL-cholesterol concentration as less than 0.9 mmol/L.~* Patients will need to be on a stable drug regimen for at least 8 weeks and not taking any chromium supplement or chromium-containing multivitamins 4 weeks prior to and during the study period. Patients can stay on their hypoglycemic or lipid-lowering medications and the required dosage will be monitored.~Exclusion Criteria:~* Patients will be excluded if there is concomitant acute infection or malignancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chromium (Type: EXPERIMENTAL): 400 μg (200 μg pills, twice per day) of Cr-nicotinate
- Placebo (Type: PLACEBO_COMPARATOR): Identical looking placebo (di-calcium phosphate)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>/=18 years of age~* Patients receiving myelosuppressive chemotherapy for a solid tumor, a hematological malignancy or an autograft for hematological malignancy~* Patients for whom treatment with epoetin beta is started at the inclusion visit~* Life expectancy \>/=6 months according to the physician~* Patients accepting and able to complete a French written questionnaire about his/her professional and social activities at each visit~Exclusion Criteria:~* Patients who received erythropoiesis-stimulating agents treatment, or red blood cell transfusion within 4 weeks before enrollment~* Participation in a clinical trial in onco-hematology~* Patients with myelodysplasia~* Patients with more than one active malignancy at the time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced or metastatic non small cell lung cancer (IIIB-IV)~* Failure of first line anti-cancer therapy (either radiological documentation of disease progression or due to toxicity) in advanced disease or subsequent relapse of disease following first line therapy~* Tumour sample confirmed as KRAS mutation positive (Note: Sample must be available upon enrolment to ship to AZ appointed central laboratory, or mutation status confirmed locally at AstraZeneca agreed local laboratory using agreed methodology, or mutation status confirmed by an accredited (eg CLIA certified) commercial laboratory (eg Genzyme or Lab 21).~Exclusion Criteria:~* Received \>1 prior anti-cancer therapy for advanced or metastatic non small cell lung cancer (excluding radiotherapy)~* Prior treatment with a MEK inhibitor or any docetaxel containing regimen (prior treatment with paclitaxel is acceptable)~* Having received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug~* Brain metastases or spinal cord compression unless asymptomatic, treated and stable off steroids and anti-convulsants for at least 1 month

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- AZD6244 + Docetaxel (Type: ACTIVE_COMPARATOR): AZD6244 75 mg bd + Docetaxel 75 mg/m\^2
- Placebo + Docetaxel (Type: PLACEBO_COMPARATOR): Placebo + Docetaxel 75 mg/m\^2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Provided signed, written informed consent.~* Has a positive result from an allergen-specific IgE antibody test.~* If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.~Exclusion Criteria:~* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.~* Presence of any abnormality or significant illness that could be expected to interfere with the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: None

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete